These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30523477)

  • 1. Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review.
    Pelechas E; Papoudou-Bai A; Voulgari PV; Drosos AA
    Rheumatol Int; 2019 Feb; 39(2):353-357. PubMed ID: 30523477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granuloma annulare induced by anti-tumour necrosis factor therapy.
    Voulgari PV; Markatseli TE; Exarchou SA; Zioga A; Drosos AA
    Ann Rheum Dis; 2008 Apr; 67(4):567-70. PubMed ID: 17728330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
    Hayakawa M; Izumi K; Higashida-Konishi M; Ushikubo M; Tsukamoto M; Akiya K; Araki K; Oshima H
    Rheumatol Int; 2019 Jan; 39(1):161-166. PubMed ID: 30357484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
    Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
    Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Granuloma Annulare.
    Ţăranu T; Grigorovici M; Constantin M; Toader MP
    Acta Dermatovenerol Croat; 2017 Dec; 25(4):292-294. PubMed ID: 30064602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab-associated localized granuloma annulare (SAGA): a case report and review of the literature.
    Fox JD; Aramin H; Ghiam N; Freedman JB; Romanelli P
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
    Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
    J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
    Matsuno H; Katayama K
    Mod Rheumatol; 2017 Mar; 27(2):246-251. PubMed ID: 27550060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
    Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
    Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series.
    Talotta R; Atzeni F; Batticciotto A; Ditto MC; Gerardi MC; Sarzi-Puttini P
    J Med Case Rep; 2018 Jun; 12(1):154. PubMed ID: 29859543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 14. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
    Mitchell E; Jones G
    Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case of granuloma annulare after using tocilizumab.
    Katsuda K; Arase N; Nakagawa Y; Tanemura A; Fujimoto M
    J Dermatol; 2020 Apr; 47(4):e117-e119. PubMed ID: 32011748
    [No Abstract]   [Full Text] [Related]  

  • 17. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):26-32. PubMed ID: 24261755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.
    Haraoui B; Casado G; Czirják L; Taylor A; Bernasconi C; Reiss W; Caporali R
    Clin Exp Rheumatol; 2017; 35(6):899-906. PubMed ID: 28516886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.